Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

NCT05284617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: HU6
DRUG: Placebo

Sponsor

Rivus Pharmaceuticals, Inc.